open access

Vol 17, No 4 (2010)
Review articles
Published online: 2010-07-27
Submitted: 2013-01-14
Get Citation

Safety of pharmacotherapy of osteoporosis in cardiology patients

Tomasz Zapolski, Andrzej Wysokiński
Cardiol J 2010;17(4):335-343.

open access

Vol 17, No 4 (2010)
Review articles
Published online: 2010-07-27
Submitted: 2013-01-14

Abstract

The commonest medical conditions following menopause are osteoporosis and atherosclerotic disease. This review considers the safety of pharmacotherapy of osteoporosis in cardiology patients. Drugs used for osteoporosis treatment may have adverse effects on the cardiovascular system. This article has detailed analysed of current drug classes, such as the bisphosphonates and strontium ranelate, as well as reviewed of the controversy surrounding hormone replacement therapy (HRT) and the selective estrogen receptor modulators (SERMs). Additionally, we discuss the adverse effects on the heart of calcium and drugs influencing calcium metabolism such as vitamin D, parathormone and calcitonin. We look at the interference between osteoporosis treatment and the drugs used for atherosclerosis. Moreover, the side effects on bones of cardiology drugs are analysed. Lastly, the possible advantages of selected drugs used for cardiovascular diseases in terms of osteoporosis prevention are evaluated.
(Cardiol J 2010; 17, 4: 335-343)

Abstract

The commonest medical conditions following menopause are osteoporosis and atherosclerotic disease. This review considers the safety of pharmacotherapy of osteoporosis in cardiology patients. Drugs used for osteoporosis treatment may have adverse effects on the cardiovascular system. This article has detailed analysed of current drug classes, such as the bisphosphonates and strontium ranelate, as well as reviewed of the controversy surrounding hormone replacement therapy (HRT) and the selective estrogen receptor modulators (SERMs). Additionally, we discuss the adverse effects on the heart of calcium and drugs influencing calcium metabolism such as vitamin D, parathormone and calcitonin. We look at the interference between osteoporosis treatment and the drugs used for atherosclerosis. Moreover, the side effects on bones of cardiology drugs are analysed. Lastly, the possible advantages of selected drugs used for cardiovascular diseases in terms of osteoporosis prevention are evaluated.
(Cardiol J 2010; 17, 4: 335-343)
Get Citation

Keywords

osteoporosis; cardiology; pharmacotherapy; complications

About this article
Title

Safety of pharmacotherapy of osteoporosis in cardiology patients

Journal

Cardiology Journal

Issue

Vol 17, No 4 (2010)

Pages

335-343

Published online

2010-07-27

Bibliographic record

Cardiol J 2010;17(4):335-343.

Keywords

osteoporosis
cardiology
pharmacotherapy
complications

Authors

Tomasz Zapolski
Andrzej Wysokiński

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk, Poland
tel.:+48 58 320 94 94, fax:+48 58 320 94 60, e-mail: viamedica@viamedica.pl